Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Gilead Sciences's price to book ratio was 17.8× on Nov 11, 2026, against 7.3× a year earlier. Over the last 5 years it ranged from 3.5× to 17.9×, with a median of 5.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.8× | +10.7 |
| 2025 | Dec 31, 2025 | 7.1× | +0.8 |
| 2024 | Dec 31, 2024 | 6.2× | +1.7 |
| 2023 | Dec 29, 2023 | 4.5× | −0.6 |
| 2022 | Dec 30, 2022 | 5.1× | +0.9 |
| 2021 | Dec 31, 2021 | 4.2× | +0.1 |
| 2020 | Dec 31, 2020 | 4.2× | +0.2 |
| 2019 | Dec 31, 2019 | 4.0× | +0.5 |
| 2018 | Dec 31, 2018 | 3.5× | −0.2 |
| 2017 | Dec 29, 2017 | 3.8× | −1.8 |
| 2016 | Dec 30, 2016 | 5.6× | −2.8 |
| 2015 | Dec 31, 2015 | 8.4× | −2.1 |
| 2014 | Dec 31, 2014 | 10.5× | −0.1 |
| 2013 | Dec 31, 2013 | 10.6× | +4.1 |
| 2012 | Dec 31, 2012 | 6.5× | +1.4 |
| 2011 | Dec 30, 2011 | 5.1× | −0.1 |
| 2010 | Dec 31, 2010 | 5.2× | −1.7 |
| 2009 | Dec 31, 2009 | 6.9× | – |
See a number that looks wrong?